Elysium Health’s first product, a supplement called Basis, is designed to support your cellular health. Basis works to increase levels of the coenzyme NAD+ in our cells. NAD+ is essential to many of our cellular functions like DNA protection, energy creation, and circadian rhythms. As we age, our levels of NAD+ decline naturally and those functions break down.
Basis is based on 25 years of aging research. Additionally, a clinical trial conducted in 2016 demonstrated that Basis increases levels of NAD+ in humans by an average of 40 percent when taken daily over the course of several weeks. The results of the trial were published in the peer-reviewed science journal npj: Aging and Mechanisms of Disease.
Elysium Health, co-founded by Dr. Leonard Guarente in 2014, works with scientists from prestigious universities such as Stanford, Yale, and Harvard. These scientists make up the scientific advisory board of the company and help guide the direction of Elysium’s research.
An individual jar of Basis costs $60, but you are probably going to want to purchase a subscription plan. A standard month-to-month subscription brings the cost of each jar down to $50 each. The most popular plan is the six-month subscription to Basis for $270 ($45 per jar). There’s also a one-year plan for $480 ($40 per jar). See This Article for more information.
Mark Mofid is a reknown plastic surgeon whom is working to make plastic surgery safer. Based in San Diego, he has worked with the top plastic surgeons with medical training at Harvard and Johns Hopkins University. He is also known for rigorous adherence to medical safety practices to ensure the safety of his patients.
Dr. Mark Mofid specializes in gluteal augmentation, which often means that patients are looking to pay more for different results. Even when his patients are looking to pay more for services, he always puts their best interest in mind when considering all of the possible treatment options.
This also means that Mark Mofid is at the top of his game in using innovative practices. Supported by science, he uses a surgical method and procedure which is subject to rigorous examination due to a deep understanding of the body. He had an aim of re-inventing the plastic surgery industry as a whole.
Dealing with incompatible implants, Dr. Mark Mofid decided to re-examine all of the available options that his patients have for gluteal implants. He determined that the majority of implants were too generic for most patients, so he decided to re-examine the options which were presented to him. See Related Link for more information.
After hours of research, he designed a implant of his own. This implant was designed to look better and have a lower profile than other implants on the market. What is even more impressive is that he invested his own money into the new implant design. Industry innovators look to Dr. Mark Mofid as an example of how things can be done right.
He has earned a reputation as being “the glute specialist” for having one of the brightest minds in glute surgery. He has a private practice and is also a staff surgeon at Scripps Memorial Hospital. Dr. Mofid is also active in the local community in an aim to assist cancer patients as a form of giving back.
Jeanmarie Guenot is currently the president of one of the biggest firm, Amphivena Therapeutics Inc, dedicated to manufacturing immune therapies to help in treating cancer. She has had the opportunity of serving the medical industry in both public and private sector for more than twenty years. She is the founder of Guenot LLC; a company specialized in offering consultation services such as licensing, economic planning, project management, mergers and acquisitions, alliance management services to both pharmaceuticals and biotechnology organizations. JeanMarie is also involved in pharmaceutical products and venture capital, project management and commercial development.
Prior to becoming the Amphivena president, Jeanmarie had an opportunity of gaining her experience from working in different firms in various roles. She once served as a business consultant for one year for Hoffmann. She worked at PDL BioPharma as a VP of Business and Corporate Development that assisted in shaping her leadership skills. As the VP, she oversaw the licensing, acquisitions and managed R&D commercial portfolios. To acknowledge all her efforts, she was awarded the BioBusiness Network Innovative Bio-Partnering Award which was in 2005 for being able to make a 50-50 deal between PDL and Hoffmann-La Roche.
LinkedIn portrays JeanMarie as an individual who is fully trained in designing drugs, semi-empirical methods, refinement, medicinal and physical chemistry and so on. Her education has played a bigger role in her career journey as she studied at the University of California where she earned her Ph.D. and MBA from the University of Pennsylvania. In specific, her scientific career started at Hoffmann while her business career began at Atlas Ventures. At Hoffmann, she was the principal scientist where she helped in developing drugs for inflammation, oncology, autoimmune and metabolic diseases. At Atlas Ventures, she majorly managed the ventures capital investments.
Jeanmarie Guenot continues working hard knowing that with what she is doing, a life is saved somewhere and a cancer patient gets a second chance at life.